Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration

被引:21
作者
Tucci, Michael A.
Ganter, Michael T.
Hamiel, Christine R.
Klaghofer, Richard
Zollinger, Andreas
Hofer, Christoph K.
机构
[1] Triemli City Hosp Zurich, Inst Anaesthesiol & Intens Care Med, CH-8063 Zurich, Switzerland
[2] Univ Lausanne Hosp, Inst Anasthesiol, Lausanne, Switzerland
[3] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA
[4] Univ Colorado, Hlth Sci Ctr, Div Cardiothorac Surg, Denver, CO USA
[5] Univ Zurich Hosp, Dept Psychosocial Med, CH-8091 Zurich, Switzerland
关键词
D O I
10.1016/j.jtcvs.2006.01.041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Reliable platelet function monitoring is desirable in patients treated with glycoprotein IIb/IIIa receptor inhibitors. The aim of the present laboratory-based study was to assess platelet function after administration of clinically relevant doses of the glycoprotein IIb/IIIa antagonist tirofiban with or without heparin by using Sonoclot (Sienco Inc) and platelet aggregometry. Methods: Tirofiban (0- 100 ng . mL(-1)) and heparin ( 0 or 1 U . mL(-1)) were added to blood samples obtained from 20 healthy volunteers. Coagulation analysis was performed on citrated whole blood by using the Sonoclot analyzer. The glass bead - activated test and the new glass bead test with heparinase were used. The results were compared with adenosine-5'-diphosphate - activated platelet aggregometry. Results: Administration of tirofiban showed a similar increase of platelet inhibition detected with the Sonoclot glass bead - activated test and glass bead test with heparinase, as well as by means of aggregometry. Bias between the different techniques was comparable; Spearman rank correlation was strong ( glass bead activated test vs aggregometry: rho = 0.823, P <.001; glass bead test with heparinase vs aggregometry: rho = 0.856, P <.001). After additional administration of heparin, platelet inhibition was only comparable for the glass bead test with heparinase and aggregometry, and the correlation coefficient remained unchanged for the glass bead test with heparinase versus aggregometry (rho = 0.878, P <.001). By contrast, the glass bead - activated test showed a nearly complete platelet inhibition with a significant bias compared with the glass bead test with heparinase and aggregometry. Correlation was weak for the glass bead - activated test versus aggregometry (rho = 0.407, P =.004). Conclusions: When compared with platelet aggregometry, the glass bead - activated test from Sonoclot reliably detects glycoprotein IIb/IIIa receptor inhibition with tirofiban in unheparinized whole blood. However, in heparinized blood the glass bead test with heparinase is essential to accurately assess platelet function.
引用
收藏
页码:1314 / 1322
页数:9
相关论文
共 26 条
[1]  
Anne G, 2004, EXPERT OPIN PHARMACO, V5, P335
[2]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1488
[3]   Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting [J].
Bizzarri, F ;
Scolletta, S ;
Tucci, E ;
Lucidi, M ;
Davoli, G ;
Toscano, T ;
Neri, E ;
Muzzi, L ;
Frati, G .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (06) :1181-1185
[4]   Successful use of recombinant factor VIIa in a patient with intractable bleeding during extracorporeal membrane oxygenation [J].
Brose, S ;
Sirbu, H ;
Engel, M ;
Kuhlen, R ;
Autschbach, R .
THORACIC AND CARDIOVASCULAR SURGEON, 2005, 53 (06) :389-390
[5]   Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment [J].
Brown, DL .
HEART, 2003, 89 (05) :535-537
[6]   Sonoclot coagulation analysis:: A study of test variability [J].
Ekbäck, G ;
Carlsson, O ;
Schött, U .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1999, 13 (04) :393-397
[7]  
Forestier F, 2001, CAN J ANAESTH, V48, P902, DOI 10.1007/BF03017358
[8]   Abciximab and excessive bleeding in patients undergoing emergency cardiac operations [J].
Gammie, JS ;
Zenati, M ;
Kormos, RL ;
Hattler, BG ;
Wei, LM ;
Pellegrini, RV ;
Griffith, BP ;
Dyke, CM .
ANNALS OF THORACIC SURGERY, 1998, 65 (02) :465-469
[9]   Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery [J].
Genoni, M ;
Zeller, D ;
Bertel, O ;
Maloigne, M ;
Turina, M .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (03) :630-632
[10]  
Hanrath P, 1997, CIRCULATION, V96, P1445